Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications

Maria D. Llorente, Victoria Urrutia

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

Antipsychotic medications are frequently prescribed by nonpsychiatric clinicians, and the use of atypical antipsychotics is increasing. Although these medications have some efficacy and tolerability advantages over the conventional drugs, they have recently been differentially associated with an increased risk of weight gain, diabetes, and hypertriglyceridemia. In the frail geriatric population with diabetes and BPSDs, these medicines have been additionally associated with a possible increased risk of cerebrovascular events and higher mortality rates. In children and adolescents, a working knowledge of child development and recognition of the influence of psychological factors on treatment adherence is critical. Screening for cardiovascular and metabolic risk factors is particularly important when atypical antipsychotics are to be prescribed. This baseline screening should include questions about personal and family history of diabetes risk factors and measurement of blood pressure, fasting glucose, and serum lipids. Diabetes risk reduction, including nutritional and physical activity counseling, control of blood pressure, lowering of cholesterol and triglyceride levels, weight loss, and increased physical activity, can have a positive impact on both diabetes and the psychiatric illnesses and can be successfully utilized in patients with schizophrenia.

Original languageEnglish (US)
Pages (from-to)18-24
Number of pages7
JournalClinical Diabetes
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Antipsychotic Agents
Psychiatry
Exercise
Blood Pressure
Hypertriglyceridemia
Risk Reduction Behavior
Child Development
Geriatrics
Weight Gain
Counseling
Weight Loss
Fasting
Schizophrenia
Triglycerides
Cholesterol
Psychology
Lipids
Glucose
Mortality
Serum

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Llorente, Maria D. ; Urrutia, Victoria. / Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications. In: Clinical Diabetes. 2006 ; Vol. 24, No. 1. pp. 18-24.
@article{fd85aaa7669a4a809b74c5046b8ec0e8,
title = "Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications",
abstract = "Antipsychotic medications are frequently prescribed by nonpsychiatric clinicians, and the use of atypical antipsychotics is increasing. Although these medications have some efficacy and tolerability advantages over the conventional drugs, they have recently been differentially associated with an increased risk of weight gain, diabetes, and hypertriglyceridemia. In the frail geriatric population with diabetes and BPSDs, these medicines have been additionally associated with a possible increased risk of cerebrovascular events and higher mortality rates. In children and adolescents, a working knowledge of child development and recognition of the influence of psychological factors on treatment adherence is critical. Screening for cardiovascular and metabolic risk factors is particularly important when atypical antipsychotics are to be prescribed. This baseline screening should include questions about personal and family history of diabetes risk factors and measurement of blood pressure, fasting glucose, and serum lipids. Diabetes risk reduction, including nutritional and physical activity counseling, control of blood pressure, lowering of cholesterol and triglyceride levels, weight loss, and increased physical activity, can have a positive impact on both diabetes and the psychiatric illnesses and can be successfully utilized in patients with schizophrenia.",
author = "Llorente, {Maria D.} and Victoria Urrutia",
year = "2006",
month = "1",
day = "1",
doi = "10.2337/diaclin.24.1.18",
language = "English (US)",
volume = "24",
pages = "18--24",
journal = "Clinical Diabetes",
issn = "0891-8929",
publisher = "American Diabetes Association Inc.",
number = "1",

}

Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications. / Llorente, Maria D.; Urrutia, Victoria.

In: Clinical Diabetes, Vol. 24, No. 1, 01.01.2006, p. 18-24.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications

AU - Llorente, Maria D.

AU - Urrutia, Victoria

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Antipsychotic medications are frequently prescribed by nonpsychiatric clinicians, and the use of atypical antipsychotics is increasing. Although these medications have some efficacy and tolerability advantages over the conventional drugs, they have recently been differentially associated with an increased risk of weight gain, diabetes, and hypertriglyceridemia. In the frail geriatric population with diabetes and BPSDs, these medicines have been additionally associated with a possible increased risk of cerebrovascular events and higher mortality rates. In children and adolescents, a working knowledge of child development and recognition of the influence of psychological factors on treatment adherence is critical. Screening for cardiovascular and metabolic risk factors is particularly important when atypical antipsychotics are to be prescribed. This baseline screening should include questions about personal and family history of diabetes risk factors and measurement of blood pressure, fasting glucose, and serum lipids. Diabetes risk reduction, including nutritional and physical activity counseling, control of blood pressure, lowering of cholesterol and triglyceride levels, weight loss, and increased physical activity, can have a positive impact on both diabetes and the psychiatric illnesses and can be successfully utilized in patients with schizophrenia.

AB - Antipsychotic medications are frequently prescribed by nonpsychiatric clinicians, and the use of atypical antipsychotics is increasing. Although these medications have some efficacy and tolerability advantages over the conventional drugs, they have recently been differentially associated with an increased risk of weight gain, diabetes, and hypertriglyceridemia. In the frail geriatric population with diabetes and BPSDs, these medicines have been additionally associated with a possible increased risk of cerebrovascular events and higher mortality rates. In children and adolescents, a working knowledge of child development and recognition of the influence of psychological factors on treatment adherence is critical. Screening for cardiovascular and metabolic risk factors is particularly important when atypical antipsychotics are to be prescribed. This baseline screening should include questions about personal and family history of diabetes risk factors and measurement of blood pressure, fasting glucose, and serum lipids. Diabetes risk reduction, including nutritional and physical activity counseling, control of blood pressure, lowering of cholesterol and triglyceride levels, weight loss, and increased physical activity, can have a positive impact on both diabetes and the psychiatric illnesses and can be successfully utilized in patients with schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=33244490029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33244490029&partnerID=8YFLogxK

U2 - 10.2337/diaclin.24.1.18

DO - 10.2337/diaclin.24.1.18

M3 - Review article

VL - 24

SP - 18

EP - 24

JO - Clinical Diabetes

JF - Clinical Diabetes

SN - 0891-8929

IS - 1

ER -